NCT05195918 is a Phase 1 clinical trial of EGCG 300 mg + Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Hal Chapman.

Who is sponsoring NCT05195918?

NCT05195918 is sponsored by Hal Chapman.

What drugs are being tested in NCT05195918?

Interventions in NCT05195918: EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone.

What condition does NCT05195918 study?

NCT05195918 studies Idiopathic Pulmonary Fibrosis.

Is NCT05195918 still recruiting?

NCT05195918 is currently completed. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT05195918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Completed Phase 1 Last updated 14 April 2026

What this trial tests

Phase 1 trial testing EGCG 300 mg + Nintedanib in Idiopathic Pulmonary Fibrosis in 50 participants. Completed in 19 March 2026.

Timeline

24 August 2023

Primary endpoint
19 March 2026

19 March 2026

Quick facts

Lead sponsor	Hal Chapman
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	24 August 2023
Primary completion	19 March 2026
Estimated completion	19 March 2026
Sites	7 locations across United States

Drugs / interventions tested

EGCG 300 mg + Nintedanib
EGCG 300 mg + Pirfenidone
Placebo 2 capsules + Nintedanib or Pirfenidone
EGCG 600 mg + Nintedanib
EGCG 600 mg + Pirfenidone
Placebo 4 capsules + Nintedanib or Pirfenidone

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Hal Chapman — full company profile →

Who can join

Adults 40 to 85, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis.
Cohen ML, Brumwell AN, Ho TC, Garakani K, et al · · 2024 · cited 60× · PMID 38980870 · DOI 10.1172/jci174598
Pyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis.
Contento G, Wilson JA, Selvarajah B, Platé M, et al · · 2024 · cited 11× · PMID 39315548 · DOI 10.1172/jci.insight.178453
Organoid-Guided Precision Medicine: From Bench to Bedside.
Tao B, Li X, Hao M, Tian T, et al · · 2025 · cited 10× · PMID 40321594 · DOI 10.1002/mco2.70195
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.
Giulianelli G, Cocconcelli E, Fiorentù G, Bernardinello N, et al · · 2025 · cited 3× · PMID 40323570 · DOI 10.1007/s41030-025-00296-0
Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer.
Carnazza M, Yang N, Tiwari RK, Geliebter J, et al · · 2025 · cited 2× · PMID 41226537 · DOI 10.3390/ijms262110498
Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions.
Fijolek J, Sniady A. · · 2025 · cited 1× · PMID 40649005 · DOI 10.3390/jcm14134631
Fibroblast PI3K/AKT signaling and extracellular matrix homeostasis: mechanisms, targets, and delivery challenges.
Fang C, Zeng Z, Ni B, Wen X, et al · · 2025 · PMID 41509070 · DOI 10.3389/fcell.2025.1681875

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Hal Chapman trials

Trials by the same sponsor.

NCT06265532 — Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect · Phase 1 · completed
NCT03928847 — Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05195918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hal Chapman
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing